Non-small cell lung cancer (NSCLC) is notorious for its paltry responses to first-line therapeutic regimens. In contrast to acquired chemoresistance, little is known about the molecular underpinnings of the intrinsic resistance of chemo-naïve NSCLC. Here we report that intrinsic resistance to paclitaxel in NSCLC occurs at a cell-autonomous level due to the uncoupling of mitotic defects from apoptosis. To identify components that permit escape from mitotic stress-induced death, we employed a genome-wide RNAi-based strategy, which combines a high-throughput toxicity screen with a live-cell imaging platform to measure mitotic fate. This strategy revealed that prolonging mitotic arrest with a small molecule inhibitor of the APC/Cyclosome could ...
Paclitaxel is a successful anti-cancer drug that kills cancer cells in two-dimensional culture throu...
Microtubule-targeting agents (MTAs), like taxanes and vinca alkaloids, are tubulin-binding drugs tha...
Recent efforts in cancer therapy investigations have been focused on developing a rational strategy ...
Non-small cell lung cancer (NSCLC) is notorious for its paltry responses to first-line therapeutic r...
Paclitaxel is an anti-mitotic drug that, due to its success in the clinic, has become a backbone of ...
Cell fate in response to an aberrant mitosis is governed by two competing networks: the spindle asse...
Taxol and other antimitotic agents are frontline chemotherapy agents but the mechanisms responsible ...
Microtubule-targeting agents (MTAs) are used extensively for the treatment of diverse types of cance...
Current theories suggest that mitotic checkpoint proteins are essential for proper cellular response...
An increased rate of proliferation in cancer cells, combined with abnormalities in spindle architect...
SummaryCurrent antimitotics work by perturbing spindle assembly, which activates the spindle assembl...
Anti-mitotic drugs constitute a major class of cytotoxic chemotherapeutics used in the clinic, killi...
In mitosis, the kinetochores of chromosomes that lack full microtubule attachments and/or mechanical...
Anti-cancer drugs that disrupt mitosis inhibit cell proliferation and induce apoptosis, although the...
Paclitaxel is a successful anti-cancer drug that kills cancer cells in two-dimensional culture throu...
Microtubule-targeting agents (MTAs), like taxanes and vinca alkaloids, are tubulin-binding drugs tha...
Recent efforts in cancer therapy investigations have been focused on developing a rational strategy ...
Non-small cell lung cancer (NSCLC) is notorious for its paltry responses to first-line therapeutic r...
Paclitaxel is an anti-mitotic drug that, due to its success in the clinic, has become a backbone of ...
Cell fate in response to an aberrant mitosis is governed by two competing networks: the spindle asse...
Taxol and other antimitotic agents are frontline chemotherapy agents but the mechanisms responsible ...
Microtubule-targeting agents (MTAs) are used extensively for the treatment of diverse types of cance...
Current theories suggest that mitotic checkpoint proteins are essential for proper cellular response...
An increased rate of proliferation in cancer cells, combined with abnormalities in spindle architect...
SummaryCurrent antimitotics work by perturbing spindle assembly, which activates the spindle assembl...
Anti-mitotic drugs constitute a major class of cytotoxic chemotherapeutics used in the clinic, killi...
In mitosis, the kinetochores of chromosomes that lack full microtubule attachments and/or mechanical...
Anti-cancer drugs that disrupt mitosis inhibit cell proliferation and induce apoptosis, although the...
Paclitaxel is a successful anti-cancer drug that kills cancer cells in two-dimensional culture throu...
Microtubule-targeting agents (MTAs), like taxanes and vinca alkaloids, are tubulin-binding drugs tha...
Recent efforts in cancer therapy investigations have been focused on developing a rational strategy ...